Note 14 - Segment Information

9 Months Ended

Jan. 31, 2014

Notes

Note 14 - Segment Information

NOTE 14 - SEGMENT INFORMATION

The following information is presented in accordance with ASC Topic 280, “Segment Reporting”, for the three and nine months ended January 31, 2014 and 2013; we operated in three reportable business segments - (1) natural sweetener (stevioside), (2) traditional Chinese medicines and (3) corporate and other. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations. Condensed financial information with respect to these reportable business segments for the three and nine months ended January 31, 2014 and 2013 is as follows:

	Three Months Ended January 31,		Nine Months Ended January 31,
	2014	2013	2014	2013
Revenues:
Chinese medicine – third party	$           713,896	$       1,111,530	$       1,862,718	$   2,475,830
Chinese medicine – related party	0	0	0	0
Total Chinese medicine	713,896	1,111,530	1,862,718	2,475,830
Stevioside – third party	1,680,795	687,414	4,338,845	3,615,509
Stevioside – related party	833,657	171,547	2,567,648	1,576,463
Total Stevioside	2,514,452	858,961	6,906,493	5,191,972
Total segment and consolidated revenues	$       3,228,348	$       1,970,491	$       8,769,211	$   7,667,802
Interest income (expense):
Chinese medicine	$                     92	$               1,667	$                   370	$           1,733
Stevioside	(35,573)	(1,030)	(69,101)	4,719
Corporate and other	0	0	0	1,718
Total segment and consolidated interest income (expense)	$           (35,481)	$                  637	$           (68,731)	$           8,170
Depreciation and amortization:
Chinese medicine	$             31,963	$             19,811	$             77,996	$         59,197
Stevioside	432,169	532,909	1,311,822	1,358,451
Corporate and other	81,294	0	243,881	0
Total segment and consolidated depreciation and amortization	$          545,426	$          552,720	$       1,633,699	$   1,417,648

	Three Months Ended January 31,		Nine Months Ended January 31,
	2014	2013	2014	2013
(Loss) income before income taxes:
Chinese medicine	$             98,689	$      137,625	$             47,689	$         149,002
Stevioside	(238,493)	(806,192)	(1,705,763)	(1,495,243)
Corporate and other	(26,258)	(161,718) )	(51,198)	(1,718,715
Total consolidated (loss) income before income taxes	$       (166,062) )	$    (830,285)	$      (1,709,272)	$    (3,064,956)

	January 31, 2014	April 30, 2013
Segment tangible assets:
Chinese medicine	$       648,711	$       644,073
Stevioside	14,287,922	15,081,311
Corporate and other	0	0
Total consolidated assets	$  14,936,633	$ 15,725,384